Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velarite-LTE: Long-Term Extension of Afimkibart in Atopic Dermatitis
NCT07223697Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Jan 2026
- Primary completion
- Mar 2033
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2 trial of afimkibart in atopic dermatitis (AD) (2 arms), sponsored by Roche. Primary endpoint: Percentage of Participants with Adverse Events up to 6 years. Started Jan 2026; status: active, not recruiting.
02
Drugs
afimkibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07223697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07223697.